Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Weekly Ratings on May 3, 2018

May 3, 2018 - By Carey Conley

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Corporate Logo
Big Money Sentiment decreased to 1.34 in Q4 2017. It has change of 0.28, from 2017Q3’s 1.62. The ratio worsened due to Vertex Pharmaceuticals Incorporated positioning: 53 sold and 160 reduced. 72 funds bought positions and 213 increased positions. Investors holded 231.42 million in 2017Q3 but now own 232.48 million shares or 0.46% more.
Warren Averett Asset Management Ltd Liability Co owns 2,225 shs for 0.05% of their capital. Kingdon Ltd Liability Corp stated it has 0.56% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Dupont Cap Mngmt holds 0.16% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 46,171 shs. Arizona State Retirement System holds 0.11% or 78,452 shs. Geode Capital Lc owns 0.13% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 2.61M shs. Federated Invsts Inc Pa has 49,260 shs for 0.02% of their capital. Cornerstone Advsr has 14,000 shs for 0.24% of their capital. Brown Advisory, Maryland-based fund reported 6,321 shs. Cornerstone Advisors has invested 0.1% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Opus Point Prtn Mngmt Lc stated it has 16,639 shs or 2.16% of all its holdings. 345,555 are held by Canada Pension Plan Board. Hightower Limited Liability Co holds 8,056 shs or 0.01% of its capital. Reliance Tru Comm Of Delaware invested 0.24% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Tokio Marine Asset Ltd invested in 1,569 shs. 122,000 were reported by Employees Retirement Of Texas.

Vertex Pharmaceuticals Incorporated had 43 insider sales and 0 insider buys since December 11, 2017. This’s net activity of $105.97 million. Silva Paul M also sold $342,142 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shs. Chodakewitz Jeffrey had sold 3,594 shs worth $580,304 on Monday, February 5. On Tuesday, January 2 a trade for 777 shs valued at $116,511 was made by Graney Thomas. On Tuesday, February 13 Shares for $614,001 were sold by Arbuckle Stuart A. On Wednesday, April 25 Shares for $6.49 million were sold by Parini Michael. ALTSHULER DAVID had sold 56,250 shs worth $8.83M on Tuesday, January 16.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

A total of 18 analysts rate Vertex Pharmaceuticals (NASDAQ:VRTX) as follows: 18 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:VRTX) has 25 ratings reports on May 3, 2018 according to StockzIntelligence. On Tuesday, January 2 the firm has “Buy” rating by BMO Capital Markets given. The stock rating was maintained by Guggenheim with “Buy” on Wednesday, January 31. On Thursday, February 1 Barclays Capital upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating. Barclays Capital has “Buy” rating and $200.0 target. On Tuesday, February 13 the stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Market Outperform” rating by JMP Securities. On Monday, March 5 Maxim Group maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with “Buy” rating. On Tuesday, February 13 the firm earned “Outperform” rating by Credit Suisse. On Tuesday, March 13 the rating was maintained by Cowen & Co with “Buy”. On Thursday, February 1 the rating was upgraded by Oppenheimer to “Buy”. On Wednesday, January 31 the company was maintained by Jefferies. On Thursday, February 1 the firm has “Buy” rating given by Leerink Swann. Listed here are Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) PTs and latest ratings.

27/04/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $200 New Target: $207 Maintain
27/04/2018 Broker: Oppenheimer Rating: Buy New Target: $190.0000 Maintain
04/04/2018 Broker: RBC Capital Markets Rating: Buy New Target: $199.0000 Maintain
13/03/2018 Broker: Cowen & Co Rating: Buy New Target: $200.0 Maintain
05/03/2018 Broker: Maxim Group Old Rating: Buy New Rating: Buy Old Target: $195 New Target: $200 Maintain
23/02/2018 Broker: Argus Research Rating: Buy New Target: $194.0
13/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $200 New Target: $211 Maintain
13/02/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $195 New Target: $196 Maintain
02/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $198 New Target: $200 Maintain
01/02/2018 Broker: Oppenheimer Rating: Buy New Target: $190.0 Upgrade

VRTX reached $149.19 during the last trading session after $0.28 change.Vertex Pharmaceuticals Incorporated has volume of 758,380 shares. Since May 3, 2017 VRTX has risen 76.59% and is uptrending. VRTX outperformed by 65.04% the S&P 500.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases.The company has $38.02 billion market cap. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs.The P/E ratio is 143.59. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: